Skip to main content
ANTX
NASDAQ Life Sciences

FDA Clears IND for Oral Epetraborole Phase 2 in Polycythemia Vera; Trial Starts Q4

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$4.54
Mkt Cap
$170.945M
52W Low
$1
52W High
$7.19
52W Position info
354% above low
Off High info
37% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

ANTX has more than doubled off its 52-week low of $1.

Summary

AN2 got FDA IND clearance for epetraborole in polycythemia vera, completing the regulatory package alongside Australia and India authorizations. The company plans to start the global Phase 2 trial in Q4 2026, an open-label sentinel and dose-optimization phase followed by a randomized, placebo-controlled cohort in phlebotomy-dependent PV patients. This is the third Phase 2 program the company expects active in 2026, per its Q2 disclosure of $79.9M in cash with runway into 2029. For a micro-cap clinical-stage name, moving a pipeline asset into the clinic is the main value driver, though the readout is years away and the $80M ATM remains an overhang. Watch for trial initiation in Q4 2026.

At the time of this announcement, ANTX was trading at $4.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $170.9M. The 52-week trading range was $1.00 to $7.19. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

ANTX - Latest Insights

ANTX
Nov 09, 2026, 7:33 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.00
Real-time Price: $4.47 info
Change: +$0.470 (+12%) info
Market Cap: $169.608M info
ANTX
Aug 11, 2026, 4:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.87
Real-time Price: $4.47 info
Change: -$1.40 (-24%) info
Market Cap: $169.608M info
ANTX
Aug 11, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.87
Real-time Price: $4.47 info
Change: -$1.40 (-24%) info
Market Cap: $169.608M info
ANTX
Aug 11, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.87
Real-time Price: $4.47 info
Change: -$1.40 (-24%) info
Market Cap: $169.608M info
ANTX
Jun 04, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.17
Real-time Price: $4.47 info
Change: +$0.300 (+7%) info
Market Cap: $169.608M info